MATINAS BIOPHARMA HOLDINGS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$2.15 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2025-11-10
- MATINAS BIOPHARMA HOLDINGS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$2.15M.
- MATINAS BIOPHARMA HOLDINGS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2024-09-30 was -$4.28M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month |
|---|---|---|
| 2025-09-30 | -$2.15M 10-Q · filed 2025-11-10 | -$9.05M 10-Q · filed 2025-11-10 |
| 2024-09-30 | -$4.28M 10-Q · filed 2025-11-10 | -$15.82M 10-Q · filed 2025-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |